within Pharmacolibrary.Drugs.ATC.L;

model L03AA10
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.1666666666666667e-07,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00017,
    k12             = 0.008,
    k21             = 0.008
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AA10</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of neutrophils. It is clinically used to reduce the duration of neutropenia and the incidence of infection in patients undergoing chemotherapy or bone marrow transplantation. Lenograstim is approved for use in several countries, but its use may vary regionally, with other G-CSFs like filgrastim or pegfilgrastim also widely available.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients receiving chemotherapy.</p><h4>References</h4><ol><li><p>Houston, AC, et al., &amp; Cour, V (1999). Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. <i>British journal of clinical pharmacology</i> 47(3) 279–284. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.1999.00888.x\">10.1046/j.1365-2125.1999.00888.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10215752/\">https://pubmed.ncbi.nlm.nih.gov/10215752</a></p></li><li><p>Akizuki, S, et al., &amp; Ohnishi, A (2000). Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. <i>Bone marrow transplantation</i> 26(9) 939–946. DOI:<a href=\"https://doi.org/10.1038/sj.bmt.1702641\">10.1038/sj.bmt.1702641</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11100272/\">https://pubmed.ncbi.nlm.nih.gov/11100272</a></p></li><li><p>Kanno, R, et al., &amp; Sugawara, M (2023). Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report. <i>Case reports in oncology</i> 16(1) 372–377. DOI:<a href=\"https://doi.org/10.1159/000530338\">10.1159/000530338</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37384199/\">https://pubmed.ncbi.nlm.nih.gov/37384199</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AA10;
